Wikidata

(Q64029840)

English

Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma

clinical trial

In more languages
default for all languages
No label defined

No description defined

Statements

short name
ReLive (English)
0 references
title
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study. (English)
0 references
country
Austria
0 references
Belgium
0 references
Egypt
0 references
France
0 references
Germany
0 references
Hungary
0 references
Italy
0 references
Lebanon
0 references
Spain
0 references
Turkey
0 references
start time
June 2012
0 references
end time
September 2017
0 references
number of participants
390
0 references
research intervention
doxorubicin
0 references
Caelyx
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64029840&oldid=2235239455"